Clinical Trials Logo

Clinical Trial Details — Status: Enrolling by invitation

Administrative data

NCT number NCT04779788
Other study ID # 20210218015
Secondary ID
Status Enrolling by invitation
Phase N/A
First received
Last updated
Start date April 1, 2021
Est. completion date June 30, 2022

Study information

Verified date July 2021
Source Xuzhou Central Hospital
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

Malignant biliary obstruction usually arise in patients suffering from primary or metastatic hepatobiliary tumors. Approximately 80% of malignant biliary obstruction patients are not eligible for surgical resection, and as such palliative stent insertion is the only treatment option available for most patients. At present, I-125 seeds loaded stent has been developed to improve the stent patency and patients' survival. Hilar malignant biliary obstruction is an important part of malignant biliary obstruction. Hilar cholangiocarcinoma is the most common disease which causes hilar malignant biliary obstruction. Herein, we assessed the clinical and long-term efficacy of I-125 seeds loaded stent insertion for hilar cholangiocarcinoma patients.


Description:

Malignant biliary obstruction usually arise in patients suffering from primary or metastatic hepatobiliary tumors. Approximately 80% of malignant biliary obstruction patients are not eligible for surgical resection, and as such palliative interventions are the only treatment option available for most patients. Of the available palliative treatments, percutaneous or endoscopic stent insertion is the most frequently used to treat malignant biliary obstruction patients. Although stent insertion can achieve the good short-term outcomes for patients with malignant biliary obstruction, stent dysfunction remains a common outcome in these treated patients, limiting the long-term efficacy of this treatment strategy. In order to overcome this shortcoming of the normal stent insertion, many researchers have developed a novel biliary I-125 seeds loaded stent. The I-125 seeds loaded stents not only can effectively relieve the jaundice, but also can provide the brachytherapy to the tumor. Previous meta-analyses also indicated that showed that relative to normal stent insertion, I-125 seeds loaded stent insertion was associated with longer survival and stent patency in inoperable malignant biliary obstruction patients. However, most previous studies included malignant biliary obstruction patients with different cancer types and malignant biliary obstruction sites, and therefore, the risk of bias did exist. Therefore, there is a clear need for a study comparing these two stent types in patients with a single type of cancer. Hilar malignant biliary obstruction is an important part of malignant biliary obstruction. Hilar cholangiocarcinoma is the most common disease which causes hilar malignant biliary obstruction. Herein, we assessed the clinical and long-term efficacy of I-125 seeds loaded stent insertion for hilar cholangiocarcinoma patients.


Recruitment information / eligibility

Status Enrolling by invitation
Enrollment 100
Est. completion date June 30, 2022
Est. primary completion date December 31, 2021
Accepts healthy volunteers No
Gender All
Age group 18 Years to 80 Years
Eligibility Inclusion Criteria: Patients with a diagnosed hilar Cholangiocarcinoma; Inoperable cases; Patients showed evidence of obstructive jaundice; Eastern Cooperative Oncology Group performance status < 4. Exclusion Criteria: Patients who underwent post-operative external radiotherapy; Patients in whom prior biliary stent insertion or drainage were performed; Patients suffering from serious dysfunction of the pulmonary, renal, cardiac, or coagulatory systems.

Study Design


Intervention

Device:
I-125 seeds loaded stent (self-expanded metal stent with I-125 seeds, Micro-Tech, Nanjing, China)
An I-125 seeds loaded stent consisted of two overlapped parts: an inner normal bare stent and an outer seeds-loaded stent
Normal stent (self-expanded metal stent without I-125 seeds, Micro-Tech, Nanjing, China)
Bare self-expanded metal stent

Locations

Country Name City State
China Xuzhou Central Hospital Xuzhou Jiangsu

Sponsors (1)

Lead Sponsor Collaborator
Xuzhou Central Hospital

Country where clinical trial is conducted

China, 

References & Publications (2)

Chen G, Zhang M, Sheng YG, Yang F, Li ZQ, Liu TG, Fu YF. Stent with radioactive seeds strand insertion for malignant hilar biliary obstruction. Minim Invasive Ther Allied Technol. 2020 Mar 3:1-7. doi: 10.1080/13645706.2020.1735446. [Epub ahead of print] — View Citation

Yang S, Liu Y, Teng F, Wu AL, Lin J, Xian YT, Xu YS. Radioactive Stent Insertion for Inoperable Malignant Common Biliary Obstruction. Surg Laparosc Endosc Percutan Tech. 2020 Aug 5;31(1):61-65. doi: 10.1097/SLE.0000000000000848. — View Citation

Outcome

Type Measure Description Time frame Safety issue
Primary Overall survival From the date of randomization until the date of first documented death from any cause. From the date of randomization until the date of first documented death from any cause, assessed up to 12 months
See also
  Status Clinical Trial Phase
Recruiting NCT05678218 - Preoperative Evaluation of Lymph Nodes of Cholangiocarcinoma
Enrolling by invitation NCT01715402 - Optimization of Health Expenditure in Liver Surgery N/A
Completed NCT03320980 - RALPPS in Patients With Hilar and Intrahepatic Cholangiocarcinoma N/A
Completed NCT00721175 - Efficacy and Cost Analysis of Plastic Stent Compare to Metallic Stent in Hilar Cholangiocarcinoma Phase 4
Recruiting NCT05626127 - MRI-based Clinico-radiomics Predicting Lymph Node Metastasis Status of Hilar Cholangiocarcinoma
Terminated NCT02082522 - Efficacy and Safety Study of PDT Using Photofrin in Unresectable Advanced Perihilar Cholangiocarcinoma (OPUS) Phase 3
Active, not recruiting NCT05239169 - Immunotherapy With Durva and Treme With or Without Capecitabine in Adjuvant Treatment for Biliary Tract Cancer Phase 2
Recruiting NCT02178280 - Safety Study of Liver Transplantation for Hilar Cholangiocarcinoma Phase 1/Phase 2
Terminated NCT02955771 - Efficacy and Safety Study of PDT Using Deuteporfin for Unresectable Advanced Perihilar Cholangiocarcinoma Phase 2
Recruiting NCT03132649 - Impact of Three-dimensional Visualization on Operation Strategy and Complications for Hilar Cholangiocarcinoma
Recruiting NCT04561453 - Feasibility Study of Multi-Platform Profiling of Resected Biliary Tract Cancer
Recruiting NCT02108145 - Percutaneous Bilateral Versus Unilateral Metal Stent for Hilar Cholangiocarcinoma Phase 2/Phase 3
Enrolling by invitation NCT03739164 - Tampa Associating Microwave Liver Ablation With Portal Vein Ligation for Staged Hepatectomy (TAMLAPS)
Recruiting NCT02801500 - Superior Bilioenteric Anastomosis by Magnetic Compressive Technique N/A
Recruiting NCT01549795 - Liver Transplantation for Hilar Cholangiocarcinoma in Association With Neoadjuvant Radio- and Chemo-therapy N/A
Recruiting NCT06106750 - Endoscopic Scissors Cutting Nasobiliary Duct VS Bilateral Plastic Stent N/A
Active, not recruiting NCT02042443 - Trametinib or Combination Chemotherapy in Treating Patients With Refractory or Advanced Biliary or Gallbladder Cancer or That Cannot Be Removed by Surgery Phase 2
Recruiting NCT05551299 - Treatment of Non-resectable Bile Duct Cancer With Radiofrequency Ablation or Photodynamic Therapy Phase 4
Completed NCT01093222 - Sorafenib Tosylate and Erlotinib Hydrochloride in Treating Patients With Locally Advanced, Unresectable, or Metastatic Gallbladder Cancer or Cholangiocarcinoma Phase 2
Completed NCT04611100 - Efficacy of Intraductal Radiofrequency Ablation in Combination With Metallic Biliary Stenting in Advanced Hilar Cholangiocarcinoma N/A